Skip to content
GLP-1 Decoder

Victoza for Weight Loss: Evidence, Eligibility, Coverage

Victoza is not FDA approved for weight loss. It is approved for type 2 diabetes and heart risk. Saxenda, with the same ingredient, is approved for weight loss. In SCALE Obesity and Prediabetes, people on Saxenda lost 7.4% of body weight on average, vs 3% on placebo.

For weight loss
Not an approved use
Active ingredient
liraglutide
How it is taken
daily injection
Best result (SCALE Obesity and Prediabetes)
7.4% weight loss

Victoza overview

How long it remains in the body
100%50%25%0%013 h26 h39 h2.2 d2.7 d50%25%12.5%time after the dose

Its half-life is about 13 hours: after 13 h, half is gone, and about 3% remains after five half-lives (2.7 d).

The main trial's weight loss result
Victoza (LEAD-3)2.5 kgPlacebo1.1 kg

In a 52-week LEAD-3 trial of type 2 diabetes, patients lost 2.5 kg, while those on placebo lost 1.1 kg.

Label reference: FDA label from DailyMed.

Who qualifies?

Victoza: who qualifies
Who sets the ruleWho qualifies
FDA labelFor adults and children aged 10 or older with type 2 diabetes, it lowers blood sugar when combined with diet and exercise.
FDA labelThis medicine lowers the chance of heart attack, stroke, or heart-related death in adults with type 2 diabetes plus heart disease.
Typical commercial plan (Aetna policy)BMI 30 or higher
Typical commercial plan (Aetna policy)BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)first comes a program of diet and activity lasting 6 months

Reference links: FDA label on DailyMed and aetna.com.

Trial results for weight loss

In this group, there is no trial for Victoza by itself. Each trial studies a brand with the same ingredient.

Trials that used the same ingredient (liraglutide)
TrialMedicineWho took partLengthPeopleMain resultComparison
SCALE Obesity and Prediabetes SaxendaAdults with obesity or overweight and no type 2 diabetes56 weeks3,7317.4% weight loss3% on placebo

Study source: SCALE Obesity and Prediabetes (FDA label (DailyMed))

What is different for weight loss?

Victoza: label points on weight loss
What changesWhat the label says
Acute PancreatitisCan cause inflammation of the pancreas. Stop taking it and get care if severe stomach pain that sometimes spreads to your back does not go away.
Acute Gallbladder DiseaseGallstones and gallbladder inflammation can happen. You must report fever, yellow skin or eyes, or upper-right belly pain.

The FDA labels provide these details: FDA label at DailyMed

Label warnings come from: FDA label on DailyMed.

Coverage for weight loss

Medicare Part D does not cover a GLP-1 used only for weight loss.

Medicaid coverage of weight-loss GLP-1s usually requires prior authorization

Sources: humana.com, KFF.

When used to lose weight

GLP-1 medicines and weight loss
MedicineFor weight lossHow it is takenTrial result
WegovyFDA approvedweekly injection or daily tablet14.9% weight loss
ZepboundFDA approvedweekly injection20.9% weight loss
FoundayoFDA approveddaily tablet11.1% weight loss
SaxendaFDA approveddaily injection7.4% weight loss
VictozaNot an approved usedaily injectionNot listed
OzempicNot an approved useweekly injectionNot listed
RybelsusNot an approved usedaily tabletNot listed
MounjaroNot an approved useweekly injectionNot listed
TrulicityNot an approved useweekly injectionNot listed
ByettaNot an approved usetwice-daily injectionNot listed

Label reference: FDA label from DailyMed.

Questions to ask your prescriber

See the full Victoza prescribing information on DailyMed.